Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation

Clinical Transplantation, Supplement

Volumn 19, Issue 14, 2005, Pages 54-58

  Miura, Masayoshi ^a   Harada, Hiroshi ^a,b   Fukuzawa, Nobuyuki ^a   Iwami, Daiki ^a   Taniguchi, Akihisa ^a   Seki, Toshimori ^a   Togashi, Masaki ^a   Ogawa, Yayoi ^a   Satoh, Hidetoshi ^a   Hirano, Tetsuo ^a  

^a SAPPORO CITY GENERAL HOSPITAL   (Japan)

^b NONE   (Japan)

Author keywords

Acute rejection; Adverse effect; Basiliximab; Immunosuppression; Renal transplantation; Tacrolimus

Indexed keywords

BASILIXIMAB; CREATININE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANAPHYLACTIC SHOCK; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION;

EID: 22244491636     PISSN: 13996738     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00393.x     Document Type: Article

References (10)

1. Ponticelli C, Yussim A, Cambi V et al. Simulect Phase IV Study Group. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001: 72: 126.
2. Lebranchu Y, Bridoux F, Buchler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002: 2: 48.
3. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003: 63: 2803.
4. Harada H, Togashi M, Seki T et al. Hyperacute onset of haemolytic-uraemic syndrome associated with hyperacute, rejection in the recipient of an ABO-incompatible kidney. Nephrol Dial Transplant 2003: 18: 1009.
5. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
6. Gonwa T, Johnson C, AhsAn N et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003: 75: 2048.
7. Horl MP, Schmitz M, Ivens K, Grabensee B. Opportunistic infections after renal transplantation. Curr Opin Urol 2002: 12: 115.
8. Siddiqi N, McBride MA, Hariharan S. Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis. Kidney Int 2004: 65: 1906.
9. Kovarik JM, Kahan BD, Rajagopalan PR et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation 1999: 68: 1288.
10. Kobayashi M, Kobayashi M, Saitoh H et al. Comparison of the incidence of diarrhea in renal transplant patients with or without mycophenolate mofetil administration. Jpn J Pharm Health Care Sci 2003: 29: 685.